Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate

Yasui,Masato; Hasegawa,Yoriko; Kawahara,Takashi; Kumano,Yohei; Miyoshi,Yasuhide; Matsubara,Nobuaki; Uemura,Hiroji

doi:10.3892/mco.2018.1573

Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate

Authors:
- Masato Yasui
- Yoriko Hasegawa
- Takashi Kawahara
- Yohei Kumano
- Yasuhide Miyoshi
- Nobuaki Matsubara
- Hiroji Uemura
View Affiliations

Affiliations: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama 232-0024, Japan, Department of Breast and Medical Oncology, National Cancer Center Hospital East, Kashiwa 277‑8577, Japan
Published online on: February 13, 2018 https://doi.org/10.3892/mco.2018.1573
Pages: 587-591

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abiraterone acetate (AA), a CYP17 inhibitor, now has a crucial role in the treatment of castration-resistant prostate cancer (CRPC), and previous studies have reported several prognostic clinical factors for AA treatment. The neutrophil‑to‑lymphocyte ratio (NLR) has also been investigated for a CRPC treatments in a few reports, however it has not been identified to be a prognostic factor for AA treatment in Japanese patients. The present study aimed to assess the association of the baseline NLR with the overall survival (OS) in CPRC patients treated by AA. The present study retrospectively reviewed a total of 90 consecutive patients with CRPC treated with AA from 2011 to 2016 at Yokohama City University Medical Center and National Cancer Center Hospital East. The primary endpoint of the study was the OS, which was defined as the survival from the start of AA administration. The secondary endpoint was the prostate‑specific antigen (PSA) response. PSA response was defined as a reduction in antigen levels of >50%. Complete blood cell counts were performed, and the NLR was calculated using the neutrophil and lymphocyte counts obtained on the same day or a few days prior to the initiation of AA therapy. The NLR cut‑off point was determined to be 3.76 for the OS, and divided into the high NLR group of 34 patients and the low NLR group of 56 patients. A PSA response was obtained in 8 patients (23.5%) in the high NLR group and in 24 (42.9%) in the low NLR group. The difference of PSA response between the two groups was significant (P=0.037). Kaplan‑Meier curves demonstrated that a high NLR [NLR ≥3.76; median OS: 8.4 months; 95% confidence interval (CI): 6.325‑10.475 months] was correlated with a risk of mortality compared with a low NLR (NLR <3.76; median OS not reached). A multivariate analysis demonstrated that the NLR was an independent predictor for the OS (hazard ratio: 2.682; 95% CI: 1.143‑6.293; P=0.023). The findings suggest that the NLR may be a useful novel biomarker for predicting the prognosis of CRPC patients treated with AA.

View Figures

View References

1	Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V and Hortobagyi GN: Squamous cell carcinoma of the breast. J Clin Oncol. 23:7827–7835. 2005. View Article : Google Scholar : PubMed/NCBI
2	Tavassoli FA and Devilee P: Metaplastic carcinomasPathology and Genetics. Tumours of the Breast and Female Genital Organs. World Organization Classification of Tumors. IARC Press; Lyon: pp. 37–38. 2003
3	Rosen PR: Chapter 21. Rosen's Breast Pathology. Lippincott-Raven; Philadelphia, New York: pp. 397–404. 1997
4	Leboit PE, Burg G, Weedon D and Sarasin A: Squamous Cell CarcinomaPathology and Genetics. Skin Tumors. World Organization Classification of Tumors. IARC Press; Lyon: pp. 20–21. 2007
5	Miranda BH, Malahias M, El-Said TF and Fahmy FS: Axillary skin malignancy: A rare breast cancer presentation. Ann Plast Surg. 72:513–514. 2014. View Article : Google Scholar : PubMed/NCBI
6	Badge SA, Gangane NM, Shivkumar VB and Sharma SM: Primary squamous cell carcinoma of the breast. Int J Appl Basic Med Res. 4:53–55. 2014. View Article : Google Scholar : PubMed/NCBI
7	Mitra B, Pal M, Debnath S, Paul B, Saha TN and Maiti A: Primary squamous cell carcinoma of breast with ipsilateral axillary lymph node metastasis: An unusual case. Int J Surg Case Rep. 2:194–197. 2011. View Article : Google Scholar : PubMed/NCBI
8	Flikweert ER, Hofstee M and Liem MS: Squamous cell carcinoma of the breast: A case report. World J Surg Oncol. 6:1352008. View Article : Google Scholar : PubMed/NCBI
9	Tsung SH: Primary pure squamous cell carcinoma of the breast might be sensitive to Cisplatin-based chemotherapy. Case Rep Oncol. 5:561–565. 2012. View Article : Google Scholar : PubMed/NCBI
10	Bhosale SJ, Kshirsagar AY, Deshmukh SJ, Jagtap SV and Langade YB: Squamous cell carcinoma of the breast. Am J Case Rep. 14:188–190. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wang J, Zhang X, He J, Yang M, Tang J, Li X, Tang H and Xie X: Co-expression of EGFR and CK5/6 in primary squamous cell carcinoma of the breast. Med Oncol. 31:1722014. View Article : Google Scholar : PubMed/NCBI
12	Porzio R, Cordini C, Orsi N, Brigati F, Paties CT and Cavanna L: Primary squamous cell carcinoma of the breast after cured bilateral breast cancer. In Vivo. 28:1155–1158. 2014.PubMed/NCBI
13	Mokhtar GA: Squamous cell carcinoma of the breast. Saudi Med J. 30:1346–1349. 2009.PubMed/NCBI
14	Sharma R, Usmani S and Siegel R: Primary squamous cell carcinoma of breast in background of phyllodes tumor-a case report. Conn Med. 73:341–343. 2009.PubMed/NCBI
15	Cichon P, Drucis K and Piotrkowski J: Primary squamous cell carcinoma of the breast-a case report. Pol Merkur Lekarski. 38:140–143. 2015.(In Polish). PubMed/NCBI
16	Samuels TH, Miller NA, Manchul LA, DeFreitas G and Panzarella T: Squamous cell carcinoma of the breast. Can Assoc Radiol J. 47:177–182. 1996.PubMed/NCBI
17	Salemis NS: Breast abscess as the initial manifestation of primary pure squamous cell carcinoma: A rare presentation and literature review. Breast Dis. 33:125–131. 2011. View Article : Google Scholar : PubMed/NCBI
18	Nair VJ, Kaushal V and Atri R: Pure squamous cell carcinoma of the breast presenting as a pyogenic abscess: A case report. Clin Breast Cancer. 7:713–715. 2007. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Yu Y, Sun JY, He SS, Wang X, Yin J and Cao XC: Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 149:133–140. 2015. View Article : Google Scholar : PubMed/NCBI
20	Behranwala KA, Nasiri N, Abdullah N, Trott PA and Gui GP: Squamous cell carcinoma of the breast: Clinico-pathologic implications and outcome. Eur J Surg Oncol. 29:386–389. 2003. View Article : Google Scholar : PubMed/NCBI
21	Shui R, Li A, Yang F, Zhou X, Yu B, Xu X and Yang W: Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. Int J Clin Exp Pathol. 7:5203–5209. 2014.PubMed/NCBI
22	Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, Peris K, Saiag P, Middleton MR, Bastholt L, et al: Diagnosis and treatment of merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer. 51:2396–2403. 2015. View Article : Google Scholar : PubMed/NCBI
23	Kurpad V, Prabhu KC, Ramesh MK and Harindranath HR: Primary denovo squamous cell carcinoma breast masquerading as breast abscess. Indian J Surg Oncol. 4:48–51. 2013. View Article : Google Scholar : PubMed/NCBI
24	Murialdo R, Boy D, Musizzano Y, Tixi L, Murelli F and Ballestrero A: Squamous cell carcinoma of the breast: A case report. Cases J. 2:73362009.PubMed/NCBI
25	Rowe DE, Carroll RJ and Day CL Jr: Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 26:976–990. 1992. View Article : Google Scholar : PubMed/NCBI
26	Schmults CD, Karia PS, Carter JB, Han J and Qureshi AA: Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: A 10-year, single-institution cohort study. JAMA Dermatol. 149:541–547. 2013. View Article : Google Scholar : PubMed/NCBI
27	Nayak A, Wu Y and Gilcrease MZ: Primary squamous cell carcinoma of the breast: Predictors of locoregional recurrence and overall survival. Am J Surg Pathol. 37:867–873. 2013. View Article : Google Scholar : PubMed/NCBI